A team of scientists in the United States of America ( USA) succeeded in developing a new method to treat various cancer by using table salt which is also known as the common salt.\r\n\r\nThe team has announced that the new method slows the growth of cancer cells by 66% but the good neighboring cells don\u2019t affect.\r\n\r\nThey studied the effect of molecules of sodium chloride on the cancer cells in a group of artificially infected rats.\r\n\r\nThe researchers found that infected cells contain a high rate of sodium but when they expose to the secondary molecules of sodium they have perished.\r\n\r\nThe other sound tissues don\u2019t face any harm at all because they handle the molecule of salt as a natural material.\r\n\r\nThe researchers affirmed that that new method will be more effective in fighting cancer of bladder, prostate, and liver.\u00a0But the team did not conduct any experiment on the human body so far to define the side effects of that method.\r\n\r\n<a href="https:\/\/see.news\/daily-routine-of-20-minutes-saves-people-from-cancer\/" target="_blank">https:\/\/see.news\/daily-routine-of-20-minutes-saves-people-from-cancer\/<\/a>\r\n\r\nSo there\u2019s good news on the cancer front. In the U.S., the cancer death rate dropped by 2.2% from 2016 to 2017, which is the largest yearly decrease ever recorded. Lower rates of lung and skin cancer deaths appear to be the biggest drivers.\r\n\r\nIt\u2019s unclear how much of the decrease can be attributed to factors such as recent advances in cancer treatments, early detection, or improved lifestyle habits like smoking cessation. But, it\u2019s probable that at least some of the progress can be attributed to better cancer treatments.\r\n\r\nNevertheless, a vexing and persistent problem in U.S. healthcare is inequality in access to treatments of all kinds, including cancer therapies.\r\n\r\nFor example, disparities in lung cancer treatment may point to an access problem. Less than 62% of lung cancer patients in the U.S. receive treatments recommended by the National Comprehensive Cancer Network (NCCN) guidelines, according to research recently published in the Annals of the American Thoracic Society. About 22% percent got no treatment, and 16% received treatment that was less intensive than recommended.\r\n\r\nThe NCCN has established clinical guidelines for treating both non-small cell lung cancer and small cell lung cancer. Together, the two types of lung cancer are the leading causes of cancer deaths in the U.S.\r\n\r\nIn \u201cDisparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the U.S.\u201d Dr. Erik Blom and colleagues report that the probability of receiving guideline-recommended treatments is even lower than 62% for African American patients and the elderly.\r\n\r\nThe findings are based on a review of nearly 442,000 lung cancer cases diagnosed between 2010 and 2014 in the U.S. National Cancer Database.\r\n\r\n<a href="https:\/\/www.forbes.com\/sites\/joshuacohen\/2020\/01\/09\/us-cancer-mortality-rate-declines-but-disparities-in-treatment-point-to-access-problems\/#3be8afa8757c" target="_blank">https:\/\/www.forbes.com\/sites\/joshuacohen\/2020\/01\/09\/us-cancer-mortality-rate-declines-but-disparities-in-treatment-point-to-access-problems\/#3be8afa8757c<\/a>\r\n\r\nAn American Story Of Service, Civic Engagement, And Citizenship\r\n\r\nThe study did not examine reasons for the disparities cited. But, an educated guess suggests several possibilities. Some patients, especially the elderly, may simply opt not to get treatment. Others, after a weighing of benefits and risks, may decide that on balance treatment is not worth it. But, for a subset of patients lack of access to healthcare is a probable reason.\r\n\r\nFor most cancer drugs, the problem in the U.S. is not on the regulatory approval side. To illustrate, the U.S. approves more oncology drugs than Europe. And, for those approved in both U.S. and Europe the time to approval tends to be shorter in the U.S.\r\n\r\nBut, regulatory approval is a necessary but insufficient condition for access. This is where insurance comes into play, as well as affordability. Insurers tend not to exclude cancer drugs from the formulary, or list of covered treatments.\r\n\r\nHowever, they often impose high rates of cost-sharing and other restrictions or conditions of reimbursement. Barriers to cancer care access can also include denials for coverage of diagnostics and mutational profiling using next-generation sequencing.